Qlaris Bio, Inc.

This is a small, early-stage study testing whether a new eye drop called QLS-111 can improve blood flow and widen blood vessels in the back of the eye. It will involve 14 people with non-proliferative diabetic retinopathy, open-angle glaucoma, or normal tension glaucoma. Particip…

This study is testing a new, preservative-free eye drop called QLS-111-FDC to see if it safely lowers eye pressure in people with open-angle glaucoma or ocular hypertension. It will compare the new drop to a standard treatment (latanoprost) over 14 days. The main goal is to see h…